Previous Close | 53.17 |
Open | 53.59 |
Bid | 51.91 x 1100 |
Ask | 52.08 x 800 |
Day's Range | 51.62 - 53.66 |
52 Week Range | 20.47 - 61.57 |
Volume | 511,068 |
Avg. Volume | 901,865 |
Market Cap | 5.968B |
Beta (5Y Monthly) | 0.72 |
PE Ratio (TTM) | 1,364.34 |
EPS (TTM) | 0.04 |
Earnings Date | Apr 26, 2021 - Apr 30, 2021 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 64.60 |
MYERS, FL / ACCESSWIRE / March 1, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Chief Financial Officer Kathryn McKenzie and Doug Brown, Chief Strategy and Corporate Development Officer will be presenting at the Virtual Raymond James 42nd Annual Institutional Investors Conference 2021, on Wednesday, March 3, 2021 at 10:50am ET.
MYERS, FL / ACCESSWIRE / February 25, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that Douglas VanOort, Chairman and Chief Executive Officer, Kathryn McKenzie, Chief Financial Officer and Doug Brown, Chief Strategy and Corporate Development Officer will be presenting at the Virtual 10th Annual SVB Leerink Global Healthcare Conference 2021, on Friday, February 26, 2021 at 10:00 am ET.
Image source: The Motley Fool. Neogenomics Inc (NASDAQ: NEO)Q4 2020 Earnings CallFeb 24, 2021, 8:30 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood morning, ladies and gentlemen, and welcome to the NeoGenomics Quarter Four and Full Year 2020 Earnings Call.